drugset
drugset / Trial / NCT07367685

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

NCT07367685 ↗

Phase 1 Not yet recruiting 6 enrolled The Second Affiliated Hospital of Fujian Medical University
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell injection solution in adult subjects with relapsed/refractory CD19-positive B-cell lymphoma.

Timeline

Start
2026-05-01
Primary completion
2028-04-30
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject QH103 Cell therapy 3e+08 cells —
Subject QH103 Cell therapy 6e+08 cells —
Background Cyclophosphamide Other / unclassified 500 mg/m2 —
Background Cyclophosphamide Other / unclassified 1000 mg/m2 —
Background Fludarabine Small molecule 30 mg/m2 —
Background Fludarabine Small molecule 40 mg/m2 —

Indications

B-cell non-Hodgkin lymphoma